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Since legalization of medical cannabis in Canada in 2001, there 
has been growing interest in the use of medical cannabinoids 
for treatment in children, fuelled by social media and a public 
perception of safety and efficacy. Legalization of medical and 
recreational cannabis appears to have, in some cases, altered the 
public perception of potential benefit and harm. However, de-
spite enthusiasm, there is scant evidence for efficacy of medical 
cannabis for most health problems in children and there is con-
cern as to potential for harm (1).
The disorders for which there is most evidence are neurologi-
cal, specifically treatment-resistant epilepsy (2). There are clini-
cal trials showing efficacy of high cannabinidiol (CBD) content 
oil for this indication (3). Epidiolex is a high CBD content phar-
macological preparation approved in the USA but not in Canada. 
There is good evidence for efficacy of cannabis-derived products 
as antiemetics; nabilone and dronabinol are synthetic canna-
binoids approved for this indication. While there is promising 
pilot work in areas such as autism, clear evidence for efficacy and 
safety is lacking. There are clinical trials underway to evaluate the 
use of medical cannabis for other conditions in children such as 
spasticity and pain that hopefully will provide evidence to guide 
the use (or non use) of medical cannabis for these conditions.
When deciding to authorize medical cannabis for a child, 
a number of practical considerations must be borne in mind. 
The decision to authorize use of medical cannabis for children 
involves considerably more effort than the prescription of other 
pharmaceuticals in that both patient/family and prescribers 
must complete much more documentation to obtain access 
to medical cannabis. An additional consideration is the degree 
of comfort that the practitioner has with the disorder in ques-
tion, as by and large the authorization of medical cannabis for 
a child is the domain of sub-specialists, for example paediatric 
epileptologists. In some circumstances authorizing and fol-
low-up may be most appropriately done by a general paedia-
trician, in which case dialogue and frequent communication 
between the paediatrician, family, and sub-specialist is essential.
If medical cannabis is a therapeutic consideration, there must be 
a comprehensive conversation with patient and family as to poten-
tial benefits and potential risks attached to the use of medical can-
nabis. This may require more than one office visit and patience in 
addressing both expectations and concerns is well advised and 
should be well documented in the patient’s health records.
If the decision is made to proceed with authorizing medical 
cannabis for a child, there are a series of decisions that need 
to be made and communicated to the patient and family. The 
first question is the therapeutic goal. What is the desired out-
come and how and when will it be monitored? At what point 
is success or lack of response determined? As well, the ques-
tion of safety must be explored. Cannabinoids can produce a 
number of adverse events, most commonly fatigue, drowsiness, 
lethargy, abdominal pain, and diarrhoea. The patient and family 
should be clear as to the potential for adverse effects, how to 
deal with them and when to report them to the health care 
team. The rate of significant adverse events varies but appears 
to be dose dependent and ranges from 5 to 15% of patients (4). 
Cannabinoids also are known to interact with other medica-
tions (5). As well, there are potential developmental issues in 
children requiring fulsome consideration and discussion (1,6).
The next question relates to the type of medical cannabis. 
Cannabis is a complex mixture of compounds, the two most 
common being delta-9 tetrahydrocannabinol, which produces 
euphoriant effects associated with marijuana, and CBD, which 
is essential for antiepileptic effects. For seizures, high CBD 
content preparations appear to be most effective. This raises 
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the question of dose. Trials have suggested a dose of CBD oil 
between 5 and 20 mg/kg/day. A dose–efficacy relationship has 
not been established but adverse effects seem to be more com-
mon at higher doses.
Many of these considerations apply to the authorizing of 
any drug to children, but are coloured in the case of medi-
cal cannabis by social media and public perception. There 
are also issues unique to medical cannabis. Once the canna-
binoid of choice and dose have been selected, the next issue 
is supply. Unlike other drugs, patients and their families may 
have to deal directly with a licensed producer of medical can-
nabis. The selection of producer is critical, as it is important 
that the cannabinoid used be in a child friendly formulation, 
the concentration be consistent lot-to-lot and that there is an 
assured supply. This often requires research on the part of the 
treatment team and the family well beyond the norm for a 
prescription.
Once a supplier has been identified, families face several 
practical issues. The first is cost. Medical cannabinoids are not 
inexpensive and do not have a Drug Identification Number 
(DIN). Many insurance companies do not reimburse for pro-
ducts without a DIN, placing the burden of payment on the 
family. An additional issue is palatability. Cannabionoid oils 
are bitter and can be difficult to administer to young children. 
Taste masking may be necessary. It cannot be over-empha-
sized that therapy should only be undertaken with cannabis 
products designed for medical use, and that using edibles 
intended for recreational use such as edible candy or ‘gummy’ 
formulations is not appropriate given the wide lot-to-lot varia-
bility in cannabinoid content.
The decision to authorize medical cannabinoids to child-
ren is difficult as is the authorization and monitoring pro-
cess. Research is urgently needed to establish efficacy, safety 
and to address the pragmatic issues facing clinicians and 
families planning to use medical cannabinoids in children. 
There are research teams, including the Canadian Paediatric 
Surveillance Program, working to ensure that Canada is a lea-
der in establishing the effective and safe use of medical canna-
bis in children.
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